Sažetak
Uvod/Cilj. Prema raspoloživim dijagnostičkim metodama nije moguće preoperativno razlikovati benigne od malignih folikulskih tumora štitaste žlezde, a najčešće ni intraoperativno zbog veoma slične ćelijske morfologije folikulskih adenoma i folikulskih karcinoma i nemogućnosti citološkog dokaza invazije kapsule ili krvnih sudova karakteristične za folikulske karcinome. U ovoj studiji, istraživali su se mogući prediktivni faktori maligniteta kod bolesnika s folikulskim karcinomom štitaste žlezde koji bi omogućili ispravnu selekciju bolesnika za hirurško lečenje, a potom i izvođenje adekvatnog tipa operacije kod bolesnika s folikulskom tireoidnom neoplazmom. Metode. Ovom retrospektivnom studijom su obuhvaćeni svi bolesnici operisani zbog postojanja folikulskog tumora štitaste žlezde u tercijarnoj univerzitetskoj zdravstvenoj ustanovi endokrine hirurgije, tokom petogodišnjeg perioda (2008–2012). U istraživanje su bila uključena 263 operisana bolesnika. Na osnovu definitivnog histopatološkog nalaza ispitanici su bili podeljeni u dve grupe: folikulske adenome (n = 97) i folikulske karcinome (n = 166). Najvažnije demografske i kliničke karakteristike operisanih bolesnika analizirane su univarijantnom i multivarijantnom logističkom regresionom analizom. Rezultati. U grupi bolesnika operisanih zbog folikulskog adenoma (19 osoba muškog i 78 ženskog pola) starosna dob je iznosila 19–79 godina s prosečnom starošću od 50 godina. U grupi bolesnika operisanih zbog folikulskog karcinoma (35 muških, 131 ženska osoba) starosna dob je bila u rasponu 15–78 godina, a prosečna starost 48 godina. Univarijantnom analizom pokazano je da se koncentracija tireoglobulina ≥ 500 ng/mL, promer tumora < 30 mm, prisustvo više od jednog tireoidnog čvora i nalaz afunkcijskog/hipofunkcijskog čvora značajno češće nalaze kod folikulskog karcinoma u odnosu na folikulski adenom. Nezavisni prediktivni faktori maligniteta bili su povišena preoperativna koncentracija tireoglobulina (≥ 500 ng/mL) i prisustvo više od jednog čvora. Ovi rezultati su, u cilju primene u praksi, prikazani i nomogramom, dvodimenzionalnim dijagramom dizajniranim da omogući približno preoperativno grafičko izračunavanje verovatnoće postojanja maligniteta. Zaključak. Povišena preoperativna koncentracija tireoglobulina, ≥ 500 ng/mL, i prisustvo više od jednog čvora su nezavisni prediktori maligniteta folikulskih karcinoma štitaste žlezde.
Ključne reči
dijagnoza
dijagnoza, diferencijalna
tireoidektomija
tireoglobulin
nomogrami
Reference
Ito Y, Miyauchi A. Prognostic Factors and Therapeutic Strate-gies for Differentiated Carcinomas of the Thyroid. Endocr J 2009; 56: 177–92.
Gulcelik NE, Gulcelik MA, Kuru B. Risk of Malignancy in Pa-tients With Follicular Neoplasm. Arch Otolaryngol Head Neck Surg 2008; 134(12): 1312–5.
Hamburger JI, Husain M. Contribution of intraoperative pa-thology evaluation to surgical management of thyroid nodules. Endocrinol Metab Clin North Am 1990; 19(3): 509–22.
Sahin M, Gursoy A, Tutuncu NB, Guverner DN. Prevalence and prediction of malignancy in cytologically indeterminate thy-roid nodules. Clin Endocrinol (Oxford) 2006; 65(4): 5148.
Miller B, Burkey S, Lindberg G, Snyder WH, Nwariaku FE. Prevalence of malignancy withincytologically indeterminate thyroid nodules. Am J Surg 2004; 188(5): 459–62.
Goldstein RE, Netterville JL, Burkey B, Johnson JE. Implications of follicular neoplasms, atypia, and lesions suspicious for ma-lignancy diagnosed by fine-needle aspiration of thyroid nod-ules. Ann Surg 2002; 235(5): 656–62.
Raber W, Kaserer K, Niederle B, Vierhapper H. Risk factors for malignancy of thyroid nodules initially identified as follicular neoplasia by fine-needle aspiration: results of a prospective study of one hundred twenty patients. Thyroid 2000; 10(8): 709–12.
Paramo JC, Mesko T. Age, tumor size, and in-office ultrasonog-raphy are predictive parameters of malignancy in follicular ne-oplasms of the thyroid. Endocr Pract 2008; 14(4): 447–51.
Petric R, Besic H, Besic N. Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small fol-licular and Hürthle cell neoplasms of the thyroid gland. World J Surg Oncol 2014; 12: 282.
Calò PG, Medas F, Santa Cruz R, Podda F, Erdas E, Pisano G, Nicolosi A. Follicular nodules (Thy3) of the thyroid: is total thyroidectomy the best option? BMC Surg 2014; 14: 12.
Zdon MJ, Fredland AJ, Zaret PH. Follicular neoplasms of the thyroid. Predictors of malignancy? Am Surg 2001; 67(9): 880–4.
Reparia K, Min SK, Mody DR, Anton R, Amrikachi M. Clinical outcomes for “suspicious” category in thyroid fine-needle bi-opsy: Patient’s sex and nodule size are possible predictors of malignancy. Arch Pathol Lab Med 2009; 133(5): 787–90.
Gulcelik NE, Gulcelik MA, Kuru B. Risk of Malignancy in Pa-tients With Follicular Neoplasm. Arch Otolaryngol Head Neck Surg 2008; 134(12): 1312–5.
Kim HJ, Mok JO, Kim CH, Kim YJ, Kim SJ, Park HK, et al. Preoperative serum thyroglobulin and changes in serum thy-roglobulin during TSH suppression independently predict fol-licular thyroid carcinoma in thyroid nodules with a cythologi-cal diagnosis of follicular lesion. Endocr Res 2017; 42(2): 154–62.
Davis NL, Gordon M, Germann E, Robins RE, McGregor GI. Clinical parameters predictive of malignancy of thyroid follic-ular neoplasms. Am J Surg 1991; 161(5): 567–9.
Najafian A, Olson MT, Schneider EB, Zeiger MA. Clinical presentation of patients with a thyroid follicular neoplasm: are there preoperative predictors of malignancy? Ann Surg Oncol 2015; 22(9): 3007–13.
Besic N, Sesek M, Peric B, Zgajnar J, Hocevar M. Predictive fac-tors of carcinoma in 327 patients with follicular neoplasm of the thyroid. Med Sci Monit 2008; 14(9): CR459–67.
Hrafnkelsson J, Tulinius H, Kjeld M, Sigvaldason H, Jónasson JG. Serum thyroglobulin as a risk factor for thyroid carcinoma. Acta Oncol 2000; 39(8): 973–7.
Panza N, Lombardi G, De Rosa M, Pacilio G, Lapenta L, Salva-tore M. High serum thyroglobulin levels. Diagnostic indicators in patients with metastases from unknown primary sites. Can-cer 1987; 60(9): 2233–6.
Suh I, Vriens MR, Guerrero MA, Griffin A, Shen WT, Duh QY, et al. Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Hurthle-cel neoplasms of the thy-roid. Am J Surg 2010; 200(1): 41–6.
Koike E, Noguchi S, Yamashita H, Murakami T, Ohshima A, Ka-wamoto H, et al. Ultrasonographic characteristics of thyroid nodules: prediction of malignancy. Arch Surg 2001; 136(3): 334–7.
Leenhardt L, Hejblum G, Franc B, Fediaevsky LD, Delbot T, Le Guillouzic D, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. J Clin Endocrinol Metab 1999; 84(1): 24–8.
Jovanovic MD, Zivaljevic VR, Diklic AD, Rovcanin BR, V Zoric G, Paunovic IR. Surgical treatment of concomitant thyroid and parathyroid disorders: analysis of 4882 cases. Eur Arch Oto-rhinolaryngol 2017; 274(2): 997–1004.